![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PRORP |
Gene summary for PRORP |
![]() |
Gene information | Species | Human | Gene symbol | PRORP | Gene ID | 9692 |
Gene name | protein only RNase P catalytic subunit | |
Gene Alias | KIAA0391 | |
Cytomap | 14q13.2 | |
Gene Type | protein-coding | GO ID | GO:0000959 | UniProtAcc | O15091 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9692 | PRORP | RNA-P17T-P17T-2 | Human | Lung | IAC | 1.99e-06 | 6.89e-01 | 0.3371 |
9692 | PRORP | RNA-P17T-P17T-4 | Human | Lung | IAC | 2.66e-08 | 7.42e-01 | 0.343 |
9692 | PRORP | RNA-P17T-P17T-6 | Human | Lung | IAC | 4.28e-05 | 6.13e-01 | 0.3385 |
9692 | PRORP | RNA-P17T-P17T-8 | Human | Lung | IAC | 1.55e-04 | 5.39e-01 | 0.3329 |
9692 | PRORP | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 1.55e-07 | 3.37e-01 | -0.2116 |
9692 | PRORP | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 2.58e-07 | 4.41e-01 | -0.2119 |
9692 | PRORP | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 2.93e-07 | 3.02e-01 | -0.0166 |
9692 | PRORP | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 4.00e-13 | 3.98e-01 | -0.0132 |
9692 | PRORP | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 3.34e-12 | 4.28e-01 | -0.013 |
9692 | PRORP | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 8.40e-12 | 4.18e-01 | -0.0121 |
9692 | PRORP | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 2.37e-02 | 3.29e-01 | -0.0961 |
9692 | PRORP | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 2.28e-04 | 3.49e-01 | -0.0876 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Lung | ![]() | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ | ||
IAC: Invasive lung adenocarcinoma | ||
MIA: Minimally invasive adenocarcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Breast | Precancer | ![]() |
Breast | IDC | ![]() |
Breast | DCIS | ![]() |
Cervix | CC | ![]() |
Cervix | HSIL_HPV | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
9692 | PRORP | NA | zileuton | ZILEUTON | 25963335 | |
9692 | PRORP | NA | zileuton | ZILEUTON | 25963335 |
Page: 1 |